Foundational Science and Mechanisms of Disease

426 questions

Question 261Question →

A 54-year-old man with a body mass index of 34 kg/m² comes to the clinic for a follow-up visit regarding his newly diagnosed type 2 diabetes mellitus. He reports struggling to adhere to his prescribed diet and exercise regimen. Laboratory studies show a fasting plasma glucose of 145 mg/dL and a hemoglobin A1c of 7.6%. The physician initiates metformin therapy and explains that the patient's condition is primarily driven by peripheral insulin resistance, which is characterized by a blunted intracellular response to endogenous insulin in target tissues. Place the following molecular events in the correct chronological sequence representing the normal cellular mechanism of insulin-mediated glucose uptake in skeletal muscle, from initial hormone binding to the final physiological effect.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence begins with insulin binding to the extracellular alpha-subunits, followed by beta-subunit autophosphorylation, phosphorylation of IRS proteins, activation of the PI3K/Akt pathway, and finally, the translocation of GLUT4 vesicles to the plasma membrane.
The normal mechanism of insulin action begins with the hormone binding to the extracellular alpha-subunits of its specific membrane receptor. This binding induces a conformational change that rapidly activates the intrinsic tyrosine kinase activity of the transmembrane beta-subunits, causing them to undergo autophosphorylation. The fully active receptor then phosphorylates critical intracellular docking proteins, most notably insulin receptor substrates (IRS-1 and IRS-2). These phosphorylated IRS proteins act as anchors for phosphoinositide 3-kinase (PI3K), which converts membrane PIP2 to PIP3. This ultimately activates Akt (Protein Kinase B), which triggers the final metabolic action in skeletal muscle and adipose tissue: the exocytosis and translocation of intracellular storage vesicles containing GLUT4 transport proteins to the plasma membrane. Once inserted into the membrane, GLUT4 permits the facilitated diffusion of glucose into the cell, thereby lowering plasma glucose levels.

Step-by-Step Solution

1
Identify the primary receptor interaction.
Insulin binds to the alpha-subunits of the receptor.
The alpha-subunits are entirely extracellular and contain the hormone-binding domains.
2
Determine the immediate intracellular consequence of receptor binding.
The beta-subunits undergo autophosphorylation.
The binding event activates the intrinsic tyrosine kinase activity located on the intracellular domains of the beta-subunits.
3
Trace the initial signal transduction steps.
Insulin receptor substrates (IRS) are phosphorylated.
The activated beta-subunit kinase targets downstream docking proteins (IRS) to propagate the signal.
4
Identify the critical kinase pathway activated by IRS.
PI3K and Akt are activated.
Phosphorylated IRS recruits and activates PI3K, initiating the PIP3/Akt cascade essential for metabolic effects.
5
Determine the final physiologic effector mechanism for glucose uptake.
GLUT4 vesicles translocate to the membrane.
Akt signaling mediates the exocytosis of pre-formed vesicles containing GLUT4 into the plasma membrane of myocytes and adipocytes.

Key Concept

The normal intracellular signaling pathway of insulin in skeletal muscle involves a receptor tyrosine kinase cascade that culminates in the membrane insertion of GLUT4 transporters to facilitate glucose uptake.
Question 262Question →

A 28-year-old female patient is evaluated at an outpatient clinic to establish primary care. She has no specific complaints, exercises regularly, and reports feeling well. She does not take any medications, over-the-counter supplements, or illicit substances. Her family history is notable for a father who was told he had "high blood calcium" years ago but never required surgery. Vital signs are within normal limits. Physical examination reveals a non-palpable thyroid gland and normal deep tendon reflexes.

Laboratory evaluation shows:
Serum calcium: 11.311.3 mg/dL (Normal: 8.4−10.28.4-10.2 mg/dL)
Serum albumin: 4.14.1 g/dL (Normal: 3.5−5.03.5-5.0 g/dL)
Serum phosphorus: 3.03.0 mg/dL (Normal: 2.5−4.52.5-4.5 mg/dL)
Intact parathyroid hormone: 5858 pg/mL (Normal: 15−6515-65 pg/mL)
24-hour urinary calcium: 4242 mg/24 hr (Normal: 100−300100-300 mg/24 hr)

Which of the following best describes the underlying molecular mechanism responsible for this patient's laboratory findings?

Show answer & explanation

Answer: Decreased sensitivity of a transmembrane G-protein-coupled receptor to extracellular cations

Answer

Decreased sensitivity of a transmembrane G-protein-coupled receptor to extracellular cations
The correct answer accurately describes the pathophysiology of Familial Hypocalciuric Hypercalcemia (FHH). FHH is a benign, autosomal dominant condition caused by a defective Calcium-Sensing Receptor (CaSR) in the parathyroid glands and kidneys. The CaSR is a transmembrane G-protein-coupled receptor. Because the receptor is less sensitive to extracellular calcium cations, higher-than-normal serum calcium levels are required to suppress parathyroid hormone (PTH) release. Simultaneously, the defective receptors in the renal tubules interpret the calcium level as falsely low, leading to maximal calcium reabsorption and thus remarkably low 24-hour urinary calcium. This patient's asymptomatic presentation, mild hypercalcemia, inappropriately normal PTH, profound hypocalciuria, and family history of benign high calcium perfectly match this mechanism.

Step-by-Step Solution

1
Analyze the patient's clinical and laboratory presentation.
The patient has asymptomatic hypercalcemia with inappropriately high-normal intact PTH (5858 pg/mL) and remarkably low 24-hour urinary calcium (4242 mg).
Establishing the complete laboratory profile is necessary to differentiate the causes of hypercalcemia.
2
Formulate a differential diagnosis based on the calcium and PTH levels.
Hypercalcemia with unsuppressed PTH narrows the differential to primary hyperparathyroidism, lithium use, and Familial Hypocalciuric Hypercalcemia (FHH).
Most other causes of hypercalcemia (malignancy, vitamin D toxicity, granulomatous disease) would result in a suppressed intact PTH level via normal negative feedback.
3
Differentiate between primary hyperparathyroidism and FHH.
The severe hypocalciuria (<100100 mg/24 hr) in the absence of thiazide diuretics, combined with a benign family history, strongly points to FHH.
Primary hyperparathyroidism typically presents with hypercalciuria or high-normal urinary calcium due to the increased filtered load of calcium overwhelming renal reabsorption.
4
Identify the molecular mechanism of FHH.
FHH is caused by an inactivating mutation of the Calcium-Sensing Receptor (CaSR), which is a G-protein-coupled receptor.
The question specifically asks for the underlying molecular mechanism.

Key Concept

Familial Hypocalciuric Hypercalcemia (FHH) is an autosomal dominant disorder caused by inactivating mutations of the Calcium-Sensing Receptor (CaSR), a G-protein-coupled receptor, leading to higher calcium levels needed to suppress PTH and increased renal calcium reabsorption.
Question 263Question →

A 35-year-old man is hospitalized for the treatment of infective endocarditis and is currently receiving his first dose of intravenous penicillin G. Ten minutes into the infusion, he develops severe pruritus, a sensation of throat tightness, and sudden shortness of breath. His temperature is 37.1°C (98.8°F), blood pressure is 82/50 mm Hg, pulse is 122/min, and respirations are 26/min. Physical examination reveals diffuse urticaria across his torso and audible expiratory wheezing.

Arrange the following management and diagnostic steps in the most appropriate chronological order for this patient's acute condition.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct chronological sequence is: 1) Cessation of the intravenous penicillin G infusion, 2) Intramuscular administration of epinephrine, 3) Administration of a rapid intravenous bolus of normal saline, 4) Intravenous administration of adjunctive medications (antihistamines and corticosteroids), and 5) Measurement of serum tryptase levels.
The established standard of care for in-hospital anaphylaxis dictates a strict hierarchy of interventions. Removing the immunologic trigger (stopping the infusion) is the universal first step. Intramuscular epinephrine is the primary life-saving medication and must be given immediately thereafter to reverse smooth muscle spasm and cardiovascular collapse. Normal saline addresses the profound third-spacing and distributive shock that follow mast cell degranulation. Adjunctive therapies like corticosteroids and antihistamines modulate the secondary inflammatory cascade and are given next. Diagnostic markers, such as serum tryptase, are only measured retrospectively once the patient is no longer in extremis.

Step-by-Step Solution

1
Identify the clinical presentation as an acute Type I IgE-mediated hypersensitivity reaction (anaphylaxis).
The patient is experiencing distributive shock and airway compromise triggered by an antibiotic infusion.
Recognizing anaphylaxis is critical for initiating the standard life-support protocol rather than treating isolated symptoms.
2
Prioritize immediate removal of the inciting antigen.
The penicillin G infusion is stopped.
Continuing the infusion would result in ongoing systemic mast cell degranulation, worsening the patient's hemodynamic collapse.
3
Administer definitive first-line pharmacotherapy.
Intramuscular epinephrine is administered into the anterolateral thigh.
Epinephrine directly reverses the life-threatening manifestations of anaphylaxis (bronchospasm and vasodilation) and stabilizes mast cell membranes.
4
Address the resulting distributive shock with volume expansion.
An intravenous bolus of normal saline is infused.
Systemic capillary leak causes significant intravascular volume depletion, necessitating rapid fluid resuscitation alongside vasopressor support.
5
Provide symptomatic relief and prevent delayed reactions.
Adjunctive corticosteroids and antihistamines are administered.
These medications do not work fast enough to be life-saving but are necessary second-line agents for ongoing inflammatory suppression.
6
Obtain diagnostic laboratory studies.
Serum tryptase levels are drawn 1 to 2 hours post-reaction.
Laboratory confirmation of mast cell degranulation must be deferred until the patient is completely stabilized.

Key Concept

The precise sequencing of interventions in anaphylaxis mandates that halting the inciting antigen and administering intramuscular epinephrine precede all fluid resuscitation, adjunctive pharmacotherapies, and diagnostic testing.
Question 264Question →

A 45-year-old woman presents to the dermatology clinic for evaluation of a suspicious skin lesion on her left posterior thigh. She states that a 'mole' she has had for over a decade has recently grown larger, developed irregular borders, and acquired varied shades of brown, black, and blue. Excisional biopsy confirms malignant melanoma with a Breslow depth of 1.8 mm. The foundational pathogenesis of this disease typically follows a well-described, stepwise evolution of cellular and structural changes. Arrange the following histopathologic and cellular phases of this patient's neoplastic process in the correct chronological sequence of classical development, from the earliest initial lesion to the most advanced stage.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct chronological sequence of melanoma pathogenesis progresses from a benign nevus, to a dysplastic nevus, followed by the radial growth phase, the vertical growth phase, and finally distant metastasis.
The pathogenesis of melanoma follows a well-defined sequence characterized by progressive accumulation of genetic mutations (such as BRAF and TP53). It begins with normal melanocytes forming a benign nevus, which can evolve into a dysplastic nevus with cytological atypia. The first truly malignant step is the radial growth phase, which is purely intraepidermal or very superficially dermal, and thus lacks metastatic capability. This is followed by a clonal evolutionary event resulting in the vertical growth phase, where cells invade the deeper dermis, establish a rich vascular network, and acquire metastatic properties. The sequence concludes with intravasation and distant metastasis.

Step-by-Step Solution

1
Identify the baseline precursor lesion.
Proliferation of structurally normal melanocytes nested along the dermoepidermal junction.
The classic Clark model of melanoma progression begins with a normal, benign junctional or compound melanocytic nevus.
2
Identify the premalignant transition phase.
Development of architectural and cytological atypia with lentiginous hyperplasia.
Subsequent genetic hits cause the benign nevus to develop into a dysplastic nevus, characterized by cytological atypia but not frank malignancy.
3
Identify the early, localized malignant phase.
Lateral intraepidermal spread of malignant melanocytes without metastatic potential.
The lesion progresses to melanoma in situ (radial growth phase), where growth is strictly horizontal along the epidermis, meaning the tumor lacks access to deeper lymphatic or blood vessels.
4
Identify the invasive malignant phase.
Invasion of malignant melanocytes into the deep dermis as an expansile mass.
The tumor transitions to the vertical growth phase, growing downward into the deeper dermal layers and acquiring the biological potential to metastasize.
5
Identify the terminal progression phase.
Tumor-induced angiogenesis, intravasation, and distant organ colonization.
Having reached the deeper vasculature during the vertical growth phase, the malignant cells disseminate systemically to form distant metastases.

Key Concept

The classic stepwise model of melanoma pathogenesis follows a sequential progression: benign melanocytic nevus → dysplastic nevus → radial growth phase (horizontal, non-metastatic) → vertical growth phase (invasive, metastatic potential) → systemic metastasis.
Question 265Question →

A physician evaluates multiple patients presenting with clinical signs of thyrotoxicosis (e.g., tachycardia, weight loss, tremor). Match the following thyroid diagnostic profiles (comprising Free T4, TSH, Radioactive Iodine Uptake [RAIU], and Thyroglobulin) with their corresponding primary pathophysiologic mechanism.

Click a left item, then click its matching right item

Items

Elevated Free T4, decreased TSH, diffusely increased RAIU
Elevated Free T4, decreased TSH, low RAIU, elevated serum thyroglobulin
Elevated Free T4, decreased TSH, low RAIU, low or undetectable serum thyroglobulin
Elevated Free T4, normal or elevated TSH, diffusely increased RAIU

Matches

Show answer & explanation

Answer

The diagnostic profiles match their mechanisms as follows: High RAIU with low TSH indicates autoantibody receptor activation; Low RAIU with high thyroglobulin indicates inflammatory destruction; Low RAIU with low thyroglobulin indicates exogenous hormone administration; High RAIU with normal/high TSH indicates autonomous pituitary secretion.
Each laboratory profile distinctly isolates a specific node in the hypothalamic-pituitary-thyroid axis. Suppressed TSH with high RAIU confirms primary de novo synthesis (Graves disease). Suppressed TSH with low RAIU and high thyroglobulin confirms release of stored hormone (Thyroiditis). Suppressed TSH with low RAIU and low thyroglobulin confirms exogenous hormone intake. Normal/high TSH with high T4 confirms secondary hyperthyroidism driven by the pituitary.

Step-by-Step Solution

1
Analyze the TSH level in the context of an elevated Free T4 to determine the anatomical source of the pathology.
A decreased TSH indicates primary hyperthyroidism or an exogenous source, whereas a normal or elevated TSH indicates a central (secondary) source.
Normal physiological negative feedback should profoundly suppress TSH in the presence of high Free T4.
2
For profiles demonstrating primary hyperthyroidism (suppressed TSH), evaluate the Radioactive Iodine Uptake (RAIU).
High RAIU indicates de novo hormone synthesis, while low RAIU indicates release of preformed hormone or an exogenous source.
RAIU measures the gland's active extraction of iodine, which only occurs when the gland is actively synthesizing new hormone.
3
For profiles with a low RAIU, assess the serum thyroglobulin level.
Elevated thyroglobulin confirms glandular destruction (thyroiditis), whereas low thyroglobulin confirms an exogenous hormone source (factitious thyrotoxicosis).
Thyroglobulin is co-released with endogenous thyroid hormone. If the gland is suppressed by exogenous hormone, thyroglobulin will be suppressed as well.

Key Concept

Differential diagnosis of thyrotoxicosis requires stepwise integration of TSH, free T4, radioactive iodine uptake, and thyroglobulin to isolate the underlying mechanism of disease.
Estimated Time:1m 30s
Question 266Question →

A 62-year-old man presents to the clinic with a 1-month history of progressive proximal muscle weakness, primarily affecting his thighs and hips. He reports significant difficulty climbing stairs and rising from a seated position, but notes that his strength temporarily improves after a few minutes of continuous walking. He has a 45-pack-year smoking history. Physical examination reveals decreased deep tendon reflexes in the lower extremities and proximal muscle weakness that transiently improves following repetitive muscle contraction. A basic metabolic panel, including serum calcium, is within normal limits. A chest radiograph demonstrates a 4.54.5-cm, centrally located left lung mass with associated hilar adenopathy. Which of the following best describes the underlying pathogenesis of this patient's neurologic symptoms and the most appropriate next step in his care?

Show answer & explanation

Answer: Production of autoantibodies against presynaptic voltage-gated calcium channels; obtain tissue biopsy of the hilar mass to confirm the suspected neuroendocrine neoplasm

Answer

Production of autoantibodies against presynaptic voltage-gated calcium channels; obtain tissue biopsy of the hilar mass to confirm the suspected neuroendocrine neoplasm
The correct answer accurately identifies the pathogenesis of Lambert-Eaton myasthenic syndrome (LEMS) as autoantibodies against presynaptic voltage-gated calcium channels. The clinical triad of proximal muscle weakness, autonomic signs (often implied or accompanied by decreased reflexes), and post-tetanic potentiation (improvement with repetitive use) is the hallmark of LEMS. In a patient with a central lung mass and heavy smoking history, LEMS is highly indicative of an underlying paraneoplastic process driven by small cell lung cancer (SCLC). The most appropriate management is to diagnose the primary tumor, which necessitates a tissue biopsy of the lung mass to confirm its neuroendocrine origin.

Step-by-Step Solution

1
Analyze the neurologic presentation.
The patient has progressive proximal muscle weakness and decreased deep tendon reflexes that improve with repetitive muscle use.
This specific pattern differentiates Lambert-Eaton myasthenic syndrome (LEMS) from Myasthenia Gravis (which worsens with use) and central nervous system lesions.
2
Correlate the neurologic findings with the patient's risk factors and imaging.
The patient has a heavy smoking history and a central lung mass with hilar adenopathy.
LEMS is a well-known paraneoplastic syndrome that is highly correlated with small cell lung cancer (SCLC), which typically presents as a central mass in smokers.
3
Determine the pathophysiologic mechanism.
LEMS is caused by autoantibodies directed against presynaptic voltage-gated calcium channels at the neuromuscular junction.
Understanding the precise molecular mechanism is required to identify the paraneoplastic process.
4
Select the most appropriate next step in management.
Tissue biopsy of the central lung mass is required.
The definitive treatment for paraneoplastic syndromes is identifying and treating the underlying malignancy. Without tissue confirmation of the neuroendocrine tumor (SCLC), appropriate oncologic management cannot begin.

Key Concept

Lambert-Eaton myasthenic syndrome (LEMS) is a paraneoplastic syndrome associated with small cell lung cancer, caused by autoantibodies against presynaptic voltage-gated calcium channels, requiring evaluation of the primary tumor.
Question 267Question →

A physician evaluates an ambulatory patient who recently developed a progressively worsening rash on both lower extremities. The patient also reports significant new-onset fatigue and bilateral pain in the metacarpophalangeal and knee joints over the past 1414 days. Medical history is significant for a diagnosis of chronic hepatitis C virus (HCV) infection confirmed several years ago, though the patient has not undergone any targeted antiviral treatment. On physical examination, the physician notes multiple non-blanching, raised, red-purple lesions distributed over the shins and calves. Joint examination shows mild, symmetric swelling without warmth. Laboratory analysis demonstrates the following:

Serum aspartate aminotransferase: 8585 U/L
Serum alanine aminotransferase: 9292 U/L
Rheumatoid factor: Positive
Complement C3: Normal
Complement C4: Markedly decreased
Urinalysis: 2+2+ protein, 1515-2020 red blood cells/hpf, occasional dysmorphic red blood cells

Which of the following immunopathologic mechanisms is most likely responsible for this patient's current clinical presentation?

Show answer & explanation

Answer: Precipitation and vessel wall deposition of circulating immune complexes containing IgG and IgM

Answer

Precipitation and vessel wall deposition of circulating immune complexes containing IgG and IgM
The correct answer accurately describes the pathophysiology of mixed cryoglobulinemia syndrome, a Type III hypersensitivity reaction. Chronic hepatitis C virus (HCV) infection provides continuous antigenic stimulation, leading to B-cell hyperactivation and the production of monoclonal or polyclonal IgM autoantibodies that possess rheumatoid factor activity. These IgM antibodies bind to the Fc portion of circulating IgG, forming immune complexes that precipitate in the cooler microvasculature of the skin, joints, and kidneys. Upon deposition in the vessel walls, these complexes aggressively activate the classical complement pathway, which preferentially consumes C4 (resulting in low serum levels while C3 often remains normal) and recruits neutrophils, ultimately causing the observed palpable purpura, arthralgias, and glomerulonephritis.

Step-by-Step Solution

1
Analyze the patient's clinical signs and risk factors.
The patient exhibits the classic triad of palpable purpura, arthralgias, and weakness, set against a background of chronic, untreated hepatitis C virus (HCV) infection.
Identifying the clinical syndrome is the first step toward recognizing the specific underlying immunologic derangement.
2
Interpret the laboratory findings.
The presence of positive rheumatoid factor, markedly low C4 with normal C3, and active urinary sediment (proteinuria, dysmorphic RBCs indicating glomerulonephritis) strongly confirm a diagnosis of mixed cryoglobulinemia syndrome.
These specific laboratory markers distinguish mixed cryoglobulinemia from other forms of systemic vasculitis or coagulopathy.
3
Connect the diagnosis to its fundamental immunopathologic mechanism.
Mixed cryoglobulinemia is driven by circulating immune complexes consisting of rheumatoid factor (IgM) binding to the Fc portion of IgG.
The deposition of these IgG-IgM complexes in small blood vessels triggers complement activation (consuming C4) and local inflammation, characteristic of a Type III hypersensitivity reaction.

Key Concept

Mixed cryoglobulinemia syndrome is a Type III hypersensitivity reaction strongly associated with chronic Hepatitis C infection. It is driven by the precipitation of circulating IgM-IgG immune complexes in small vessels, triggering classical complement activation and marked C4 consumption.
Question 268Question →

Match each pediatric patient's clinical presentation with the underlying primary immunologic defect.

Click a left item, then click its matching right item

Items

4-year-old boy with recurrent severe periodontitis, mucosal infections without pus formation, and a history of delayed umbilical cord separation
5-year-old boy with a history of recurrent Aspergillus pneumonia, suppurative lymphadenitis, and a negative (abnormal) dihydrorhodamine 123 test
6-year-old girl with recurrent pyogenic infections, partial oculocutaneous albinism, and progressive peripheral neuropathy
6-month-old boy presenting with failure to thrive, persistent oral candidiasis, and absent thymic shadow on chest radiography

Matches

Show answer & explanation

Answer

The patient with delayed cord separation matches with defective tight adhesion. The patient with Aspergillus and abnormal DHR matches with impaired phagocyte respiratory burst. The patient with partial albinism matches with defective microtubule polymerization. The patient with persistent candidiasis and absent thymus matches with impaired T-cell proliferation.
Each patient's clinical presentation precisely maps to a specific cellular or molecular defect within the innate or adaptive immune system. Identifying unique clinical clues (e.g., albinism, absent pus, absent thymus, specific diagnostic test results) correctly bridges the diagnosis to the underlying pathophysiology.

Step-by-Step Solution

1
Analyze the clinical vignette for the 4-year-old boy.
Identify Leukocyte Adhesion Deficiency (LAD) based on the classic triad of recurrent infections without pus, severe periodontitis, and delayed umbilical cord separation.
This phenotype is driven by the inability of neutrophils to exit the vasculature, pointing to defective adhesion and transmigration.
2
Evaluate the clinical vignette for the 5-year-old boy.
Identify Chronic Granulomatous Disease (CGD) indicated by infections with catalase-positive organisms (Aspergillus) and an abnormal DHR test.
The DHR test evaluates the phagocyte's ability to generate reactive oxygen species, which is impaired due to NADPH oxidase deficiency.
3
Assess the clinical vignette for the 6-year-old girl.
Identify Chediak-Higashi syndrome based on the combination of immunodeficiency, partial albinism, and neurological symptoms.
This specific symptom triad is the result of defective lysosomal trafficking and microtubule dysfunction (LYST gene mutation).
4
Review the clinical vignette for the 6-month-old boy.
Identify Severe Combined Immunodeficiency (SCID) due to early-onset opportunistic infections (thrush), failure to thrive, and absent thymic shadow.
Profound early-onset defects in cellular and humoral immunity are typically caused by profound T-cell deficiencies, commonly due to cytokine receptor defects like the IL-2 receptor gamma chain.

Key Concept

Clinical and pathophysiologic correlations of primary immunodeficiencies
Question 269Question →

Match each clinical and pathologic description of a hematologic malignancy with its defining molecular or cytogenetic mechanism.

Click a left item, then click its matching right item

Items

An adult patient evaluated for abdominal fullness is found to have massive splenomegaly. Peripheral blood evaluation reveals a leukocyte count of 110,000/µL with a complete spectrum of granulocytic differentiation.
A pediatric patient develops a rapidly enlarging, destructive tumor of the jaw. Histopathologic examination of the lesion reveals a uniform population of medium-sized lymphocytes with scattered macrophages containing apoptotic debris.
An asymptomatic older adult is noted to have persistent, generalized lymph node enlargement. Excisional biopsy shows an architectural effacement by tightly packed, uniform follicles lacking normal polarization.
A young adult is admitted to the intensive care unit with acute hemorrhage and laboratory markers indicating consumptive coagulopathy. Bone marrow analysis demonstrates an accumulation of highly granular myeloid precursors.

Matches

Show answer & explanation

Answer

Chronic Myeloid Leukemia pairs with chimeric tyrosine kinase activation; Burkitt lymphoma pairs with oncogene relocation near an immunoglobulin promoter; Follicular lymphoma pairs with overexpression of an anti-apoptotic protein; Acute Promyelocytic Leukemia pairs with a fusion gene causing maturation arrest.
Each hematologic malignancy features a distinct driving mutation that explains its pathologic behavior. CML relies on BCR-ABL1 (tyrosine kinase). Burkitt lymphoma relies on c-MYC (transcriptional activator). Follicular lymphoma relies on BCL2 (anti-apoptotic). APL relies on PML-RARA (differentiation arrest).

Step-by-Step Solution

1
Analyze the first presentation (splenomegaly, full granulocytic spectrum).
Diagnosis is Chronic Myeloid Leukemia (CML).
CML is uniquely associated with the BCR-ABL1 tyrosine kinase mutation resulting from t(9;22).
2
Analyze the second presentation (jaw tumor, 'starry sky' histology).
Diagnosis is Burkitt lymphoma.
Burkitt lymphoma is driven by c-MYC translocations involving immunoglobulin promoters, typically t(8;14).
3
Analyze the third presentation (painless adenopathy, packed follicles).
Diagnosis is Follicular lymphoma.
Follicular lymphoma is caused by t(14;18) leading to BCL2 overexpression, which prevents apoptosis.
4
Analyze the fourth presentation (hemorrhage/DIC, granular precursors).
Diagnosis is Acute Promyelocytic Leukemia (APL).
APL is caused by the PML-RARA translocation t(15;17) arresting myeloid differentiation.

Key Concept

Molecular pathogenesis of hematologic malignancies and their characteristic translocations.
Question 270Question →

Emergency medical services bring a 23-year-old male to the emergency department after his roommate found him diaphoretic, lethargic, and disoriented. The patient has a history of type 1 diabetes mellitus and recently increased his running mileage. Capillary blood glucose on arrival is 34 mg/dL. The physician promptly administers an intramuscular injection of a counter-regulatory peptide hormone, resulting in a rapid improvement of the patient's mental status and a steady rise in blood glucose over the next 15 minutes. Arrange the following intracellular and enzymatic steps in the correct chronological sequence detailing the hepatic mechanism by which this treatment reversed the patient's hypoglycemia.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The sequence begins with glucagon binding to its 7-transmembrane GPCR, triggering GDP/GTP exchange on the Gs-alpha subunit. This activates adenylyl cyclase to produce cAMP. Cyclic AMP then binds and activates protein kinase A (PKA). PKA phosphorylates phosphorylase kinase, which in turn activates glycogen phosphorylase to cleave alpha-1,4-glycosidic bonds, initiating glycogenolysis.
The correct sequence maps the precise biochemical pathway of glucagon-mediated glycogenolysis. Glucagon is a peptide hormone that binds to a 7-transmembrane Gs-coupled receptor on hepatocytes. This binding induces a conformational change allowing the Gs-alpha subunit to exchange GDP for GTP. The active Gs-alpha subunit stimulates adenylyl cyclase to convert ATP into cAMP. Increased cAMP levels bind to the regulatory subunits of Protein Kinase A (PKA), causing them to dissociate and liberate active catalytic subunits. PKA then phosphorylates and activates phosphorylase kinase. Finally, phosphorylase kinase phosphorylates glycogen phosphorylase, activating it to cleave alpha-1,4-glycosidic linkages in glycogen, yielding glucose-1-phosphate which is converted to free glucose and released into the bloodstream.

Step-by-Step Solution

1
Identify the administered medication and its target organ.
The medication is intramuscular glucagon, which primarily targets the liver to raise blood glucose.
Glucagon is the standard counter-regulatory peptide hormone used for severe hypoglycemia when intravenous access is unavailable.
2
Determine the type of receptor bound by the medication.
Glucagon binds to a Gs-protein coupled receptor (GPCR).
Peptide hormones typically act via cell surface receptors rather than intracellular receptors.
3
Trace the second messenger cascade activated by a Gs-coupled receptor.
Receptor binding causes Gs-alpha to exchange GDP for GTP. The Gs-alpha-GTP complex stimulates adenylyl cyclase to generate cAMP.
This is the universal signal transduction mechanism for all Gs-coupled GPCRs.
4
Map the downstream kinase cascade triggered by elevated cAMP.
cAMP activates Protein Kinase A (PKA), which phosphorylates phosphorylase kinase, which subsequently activates glycogen phosphorylase.
The metabolic goal is to rapidly break down stored glycogen into glucose-1-phosphate, which requires activating the rate-limiting enzyme glycogen phosphorylase.

Key Concept

Glucagon acts via a Gs-protein coupled receptor to increase cAMP, activate Protein Kinase A, and initiate a phosphorylation cascade that ultimately stimulates glycogenolysis.
Question 271Question →

A 45-year-old man is evaluated in the hospital due to a new-onset diffuse rash and severe diarrhea. He underwent an allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia four weeks ago. His current medications include tacrolimus, acyclovir, and fluconazole. His temperature is 38.2°C (100.8°F), blood pressure is 110/70 mm Hg, and pulse is 98/min. Physical examination reveals a generalized maculopapular rash that prominently involves the palms and soles. His abdomen is mildly tender to palpation, and he reports having 6 to 8 large-volume watery stools daily over the past three days. Laboratory studies show markedly elevated alkaline phosphatase and total bilirubin levels. Which of the following best describes the primary immunopathologic mechanism responsible for this patient's current clinical presentation?

Show answer & explanation

Answer: Activation of donor-derived immunocompetent T lymphocytes against recipient cellular antigens

Answer

Activation of donor-derived immunocompetent T lymphocytes against recipient cellular antigens
The clinical presentation of a maculopapular rash prominently involving the palms and soles, copious secretory diarrhea, and hepatobiliary dysfunction (evidenced by elevated alkaline phosphatase and total bilirubin) roughly four weeks after an allogeneic hematopoietic stem cell transplantation (HSCT) is the classic triad of acute graft-versus-host disease (GVHD). The fundamental mechanism underlying acute GVHD is an immunologic attack by donor-derived immunocompetent T cells (primarily CD8+ cytotoxic T cells) contained within the transplanted graft. These donor T cells recognize the recipient's human leukocyte antigens (HLAs) and minor histocompatibility antigens as foreign. This recognition triggers profound donor T-cell activation, proliferation, and subsequent targeted cell-mediated destruction of recipient epithelial cells, preferentially affecting the skin, gastrointestinal tract, and liver.

Step-by-Step Solution

1
Analyze the clinical presentation and patient history.
The patient developed a maculopapular rash (involving palms/soles), secretory diarrhea, and hepatobiliary dysfunction (elevated alkaline phosphatase and bilirubin) 4 weeks after an allogeneic stem cell transplant.
Identifying this classic clinical triad in the context of recent hematopoietic stem cell transplantation is essential to diagnose acute graft-versus-host disease (GVHD).
2
Determine the pathophysiologic mechanism of the diagnosed condition.
Acute GVHD is caused by immunocompetent donor T cells recognizing the recipient's human leukocyte antigens (HLAs) as foreign and initiating a cell-mediated immune attack.
The question specifically asks for the mechanism causing the symptoms, requiring a distinction between donor-versus-recipient and recipient-versus-donor responses.

Key Concept

Pathogenesis of acute graft-versus-host disease (GVHD)
Question 272Question →

A 62-year-old woman is evaluated in the intensive care unit for sudden-onset high fever, rigors, and altered mental status. Five days ago, she received chimeric antigen receptor (CAR) T-cell therapy for relapsed diffuse large B-cell lymphoma. Her temperature is 39.8°C (103.6°F), blood pressure is 82/45 mm Hg, pulse is 134/min, and respirations are 28/min. Oxygen saturation is 88% on room air. Physical examination reveals a lethargic patient with warm, flushed extremities. Cytokine release syndrome (CRS) is suspected, though concurrent sepsis cannot be excluded. Arrange the following management steps in the most appropriate chronological sequence for this patient's acute immunologic complication.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct chronological sequence is: 1) Initiate aggressive intravenous fluid resuscitation and provide supplemental oxygen, 2) Obtain blood cultures, urinalysis, and baseline inflammatory markers, 3) Administer empirical broad-spectrum intravenous antibiotics, 4) Administer intravenous tocilizumab to target interleukin-6 (IL-6) receptor signaling, 5) Administer intravenous dexamethasone.
The patient presents with distributive shock and hypoxia following CAR-T cell therapy, which is highly suspicious for severe cytokine release syndrome (CRS). However, sepsis is a major competing diagnosis in this immunocompromised state. The correct sequence of management prioritizes the ABCs (Airway, Breathing, Circulation) by first initiating fluid resuscitation and oxygenation. The second critical step is obtaining diagnostic blood cultures and baseline inflammatory markers (C-reactive protein, ferritin), which must precede antimicrobial administration to avoid sterilizing the cultures. Third, broad-spectrum empiric antibiotics must be given immediately, as untreated sepsis is rapidly fatal. Fourth, targeted CRS therapy with tocilizumab (an IL-6 receptor antagonist) is administered. Finally, systemic corticosteroids like dexamethasone are utilized only if the patient remains hemodynamically unstable despite tocilizumab, as corticosteroids can blunt the therapeutic effect of the CAR-T cells.

Step-by-Step Solution

1
Stabilize hemodynamics and oxygenation.
The patient receives intravenous fluids and supplemental oxygen.
ABCs (Airway, Breathing, Circulation) are the universal first priority in any unstable patient, regardless of the underlying etiology.
2
Perform diagnostic workup for infection and systemic inflammation.
Blood cultures and inflammatory markers are drawn.
Infection must be ruled out in immunocompromised patients, and baseline CRS markers (CRP, ferritin) are needed to monitor treatment response. This must occur before antibiotics are given.
3
Administer empiric antibiotics.
The patient receives broad-spectrum antimicrobial coverage.
Because neutropenic sepsis can rapidly lead to death and mimics CRS, empiric antibiotics are mandatory immediately after cultures are obtained.
4
Initiate specific targeted therapy for CRS.
Tocilizumab (anti-IL-6 receptor monoclonal antibody) is administered.
Once the patient is stabilized and potential infection is covered, targeted inhibition of the cytokine storm (specifically IL-6) is indicated for severe CRS.
5
Escalate immunosuppression if refractory.
Corticosteroids are administered.
Corticosteroids broadly suppress the immune response, including the therapeutic CAR-T cells, so they are reserved for cases that do not respond to tocilizumab or if severe neurotoxicity develops.

Key Concept

The management of severe cytokine release syndrome requires initial hemodynamic stabilization and sepsis workup, followed by empirical antibiotics, before escalating to targeted anti-IL-6 therapy (tocilizumab) and, if refractory, systemic corticosteroids.
Question 273Question →

A 58-year-old man with a 10-year history of type 2 diabetes mellitus is brought to the emergency department by his wife due to severe nausea, vomiting, and generalized weakness for the past 48 hours. He recently had a viral upper respiratory infection and has had poor oral intake. His medications include metformin, empagliflozin, and lisinopril. Vital signs show a blood pressure of 98/6298/62 mmHg, heart rate of 115115/min, and respiratory rate of 2424/min. Physical examination reveals dry mucous membranes.

Laboratory studies show:

Laboratory TestResultReference Range
Serum sodium136136 mEq/L136−145136-145 mEq/L
Serum potassium4.84.8 mEq/L3.5−5.03.5-5.0 mEq/L
Serum chloride102102 mEq/L95−10595-105 mEq/L
Serum bicarbonate1212 mEq/L22−2822-28 mEq/L
Blood urea nitrogen3434 mg/dL7−187-18 mg/dL
Serum creatinine1.61.6 mg/dL0.6−1.20.6-1.2 mg/dL
Serum glucose178178 mg/dL70−11070-110 mg/dL
Serum ketonesPositiveNegative

Arterial blood gas analysis reveals a pH of 7.247.24.

Which of the following is the most direct underlying metabolic mechanism precipitating this patient's primary acid-base disturbance?

Show answer & explanation

Answer: Increased ratio of circulating glucagon to insulin

Answer

Increased ratio of circulating glucagon to insulin
The patient presents with a high anion-gap metabolic acidosis (136−102−12=22136 - 102 - 12 = 22 mEq/L) and positive serum ketones, diagnostic of diabetic ketoacidosis (DKA). However, his blood glucose is unexpectedly low for standard DKA presentation (178178 mg/dL). This presentation is characteristic of euglycemic DKA, a known, life-threatening adverse effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors like empagliflozin. SGLT2 inhibitors block proximal tubular glucose reabsorption, resulting in massive, continuous glycosuria. This artificially lowers serum glucose, which in turn decreases pancreatic beta-cell insulin secretion and strongly stimulates alpha-cell glucagon release. The resulting high glucagon-to-insulin ratio promotes severe lipolysis, releasing free fatty acids that undergo hepatic oxidation into ketone bodies. The physiologic stress of his recent viral infection and subsequent poor oral intake further exacerbated this dangerous glucagon-heavy metabolic state.

Step-by-Step Solution

1
Calculate the serum anion gap to classify the primary acid-base disturbance.
Anion gap = 136−(102+12)=22136 - (102 + 12) = 22 mEq/L.
An elevated anion gap (>12>12 mEq/L) restricts the differential diagnosis to specific causes such as ketoacidosis, lactic acidosis, uremia, or toxin ingestion.
2
Correlate the high anion gap with the patient's specific lab findings and medication history.
The patient has positive serum ketones but a relatively normal blood glucose level (178178 mg/dL) while actively taking an SGLT2 inhibitor (empagliflozin).
Positive ketones confirm ketoacidosis. The absence of marked hyperglycemia (glucose <250<250 mg/dL) points to euglycemic diabetic ketoacidosis, a classic complication of SGLT2 inhibitors.
3
Identify the primary cellular and hormonal mechanism of SGLT2 inhibitor-induced euglycemic ketoacidosis.
SGLT2 inhibitors cause profound urinary glucose loss, decreasing blood glucose levels, which subsequently decreases insulin secretion and drastically increases glucagon secretion.
The resulting high glucagon-to-insulin ratio directly stimulates hepatic lipid oxidation and ketogenesis, causing the profound ketoacidosis seen in the presentation.

Key Concept

Sodium-glucose cotransporter-2 (SGLT2) inhibitors can precipitate euglycemic diabetic ketoacidosis by inducing profound glycosuria, creating a state of relative insulin deficiency and marked glucagon excess that drives ketogenesis.
Question 274Question →

A 61-year-old man is diagnosed with advanced non-small cell lung cancer. Immunohistochemical analysis of his biopsy specimen reveals a high tumor mutational burden and robust expression of programmed death-ligand 1 (PD-L1). He is initiated on pembrolizumab, an immune checkpoint inhibitor. The pathogenesis of this patient's pre-treatment immune evasion relies on a specific sequence of cellular interactions collectively known as adaptive immune resistance. Arrange the following pathophysiological events in the chronological order that leads to tumor-induced T-cell anergy.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence begins with dendritic cell presentation of neoantigens, followed by T-cell infiltration into the tumor, secretion of interferon-gamma by these T cells, subsequent adaptive upregulation of PD-L1 by the tumor cells, and finally the ligation of PD-1 receptors causing T-cell exhaustion.
The correct sequence describes the phenomenon of adaptive immune resistance. Initially, tumor cell turnover releases neoantigens that are taken up by dendritic cells and presented to naive T cells in the draining lymph nodes. These activated, antigen-specific CD8+ T cells then traffic to and infiltrate the tumor microenvironment. Upon recognizing their target antigens, the infiltrating T cells secrete pro-inflammatory cytokines, most notably interferon-gamma. In a counter-regulatory survival mechanism, the neoplastic cells respond to this local interferon-gamma exposure by adaptively upregulating PD-L1 on their cell surfaces. Finally, the newly expressed PD-L1 binds to PD-1 receptors on the activated T cells, sending an intracellular inhibitory signal that induces T-cell exhaustion, anergy, and apoptosis, thereby shielding the tumor from immune-mediated destruction.

Step-by-Step Solution

1
Identify the initiating event of the anti-tumor immune response.
Dendritic cell cross-presentation of tumor-derived neoantigens.
Naive T cells require professional antigen-presenting cells in the lymphoid organs to become activated against novel tumor antigens.
2
Determine the required step following T-cell activation in the lymph nodes.
Infiltration of the tumor microenvironment by activated CD8+ T cells.
Activated T cells must physically traffic from the lymphoid tissue to the site of the neoplasm to exert their effector functions.
3
Identify the primary action of T cells upon recognizing the tumor.
Secretion of pro-inflammatory cytokines, specifically interferon-gamma.
Cytotoxic T cells release cytokines like interferon-gamma to orchestrate the destruction of the recognized malignant cells.
4
Recognize the tumor's counter-regulatory cellular response.
Adaptive upregulation of programmed death-ligand 1 (PD-L1).
Tumors utilize the interferon-gamma signal to adaptively upregulate PD-L1, attempting to subvert the ongoing immune attack.
5
Identify the final mechanism of action for T-cell suppression.
Ligation of T-cell surface PD-1 receptors resulting in functional exhaustion.
PD-L1 binding to the PD-1 checkpoint receptor directly halts T-cell proliferation and cytotoxic activity, completing the immune evasion sequence.

Key Concept

The mechanism of adaptive immune resistance and dynamic PD-L1 upregulation within the tumor microenvironment.
Question 275Question →

Match each patient's clinical presentation with the autoantibody most specifically associated with their underlying immunologic pathology.

Click a left item, then click its matching right item

Items

A 28-year-old woman with a photosensitive malar rash, inflammatory arthritis, and new-onset nephrotic-range proteinuria.
A 45-year-old woman with dysphagia, skin thickening restricted to her fingers and face, and episodic digital vasospasm in the cold.
A 50-year-old man with progressive symmetric proximal muscle weakness, interstitial lung disease, and violaceous papules over his knuckles.
A 35-year-old woman with severe bilateral keratoconjunctivitis sicca, xerostomia, and an increased risk of B-cell lymphoma.

Matches

Show answer & explanation

Answer

The clinical syndromes correctly map to the following markers: SLE with anti-dsDNA, CREST syndrome with anti-centromere, dermatomyositis (antisynthetase syndrome) with anti-Jo-1, and Sjögren syndrome with anti-Ro/SSA and anti-La/SSB.
Each clinical vignette presents a classic constellation of symptoms for a distinct rheumatologic or autoimmune disease. Correctly diagnosing the underlying condition from the clinical presentation allows for the accurate identification of its most specific autoantibody, which is crucial for confirming the diagnosis, assessing patient prognosis, and guiding targeted management strategies.

Step-by-Step Solution

1
Analyze the first clinical vignette to identify Systemic Lupus Erythematosus (SLE) complicated by lupus nephritis.
Matched with its highly specific marker, anti-dsDNA.
Anti-dsDNA correlates with SLE disease activity, flares, and subsequent renal damage.
2
Identify the second vignette as limited cutaneous systemic sclerosis (CREST syndrome) based on the presence of Raynaud phenomenon, esophageal issues, and sclerodactyly.
Matched to anti-centromere antibodies.
Anti-centromere is the defining autoantibody for the limited cutaneous form of systemic sclerosis.
3
Recognize the third vignette as dermatomyositis with associated interstitial lung disease, characteristic of antisynthetase syndrome.
Matched to anti-Jo-1 antibodies.
Anti-Jo-1 (an anti-tRNA synthetase) is highly specific for inflammatory myopathies that present with interstitial lung disease and mechanic's hands.
4
Diagnose the fourth vignette as Sjögren syndrome based on the prominent sicca symptoms and the well-documented heightened risk for B-cell lymphoma.
Matched to anti-Ro/SSA and anti-La/SSB antibodies.
These specific ribonucleoprotein antibodies are the hallmark serological findings required to formalize a Sjögren syndrome diagnosis.

Key Concept

Identifying specific autoantibodies for rheumatologic and autoimmune diseases based on clinical manifestations is essential for establishing an accurate diagnosis, anticipating organ involvement, and predicting disease complications.
Question 276Question →

A 5858-year-old man is evaluated in the emergency department for severe, acute-onset pain, swelling, and redness of his right knee. He is a renal transplant recipient and his current immunosuppressive regimen includes azathioprine, tacrolimus, and low-dose prednisone. He also has a history of peptic ulcer disease with a recent gastrointestinal hemorrhage. His temperature is 37.8∘C37.8^\circ\text{C} (100.0∘F100.0^\circ\text{F}). Serum laboratory studies show a creatinine level of 2.9 mg/dL2.9\text{ mg/dL} and a uric acid level of 5.8 mg/dL5.8\text{ mg/dL} (normal: 4.0−8.5 mg/dL4.0-8.5\text{ mg/dL}). Joint aspiration yields cloudy synovial fluid with a leukocyte count of 55,000/μL55,000/\mu\text{L} (85%85\% neutrophils) and negatively birefringent, needle-shaped crystals. Due to the patient's medical history, several standard therapies are deemed high-risk. The physician decides to administer a targeted biologic agent appropriate for the acute management of this condition. Inhibition or neutralization of which of the following is the primary mechanism of action of the most appropriate therapy for this patient's current symptoms?

Show answer & explanation

Answer: Interleukin-1 beta

Answer

Interleukin-1 beta
The patient is experiencing an acute gout flare, confirmed by the pathognomonic finding of negatively birefringent, needle-shaped crystals in the synovial fluid. The fundamental immunologic process of acute gout involves the phagocytosis of monosodium urate crystals by macrophages. These intracellular crystals trigger the assembly of the NOD-like receptor pyrin domain-containing 3 (NLRP3) inflammasome. The inflammasome activates caspase-1, which subsequently cleaves pro-interleukin-1 beta into active Interleukin-1 beta (IL-1β), a potent pro-inflammatory cytokine. When conventional first-line agents for acute gout (NSAIDs, colchicine) are strictly contraindicated—such as in this patient with advanced chronic kidney disease and a recent gastrointestinal hemorrhage—IL-1β inhibitors (e.g., anakinra, canakinumab) are the most appropriate targeted biologic therapies to neutralize the specific cytokine driving the disease.

Step-by-Step Solution

1
Diagnose the acute joint pathology based on the synovial fluid analysis.
The presence of negatively birefringent, needle-shaped crystals within a highly cellular, neutrophil-predominant synovial fluid confirms a diagnosis of acute gouty arthritis, despite the normal serum uric acid level.
Accurate identification of the crystal type dictates the specific inflammatory pathway driving the disease.
2
Evaluate the patient's comorbidities against standard gout treatments to determine contraindications.
NSAIDs are contraindicated due to chronic kidney disease and recent peptic ulcer bleeding. Colchicine is contraindicated due to severe renal impairment. Allopurinol is for chronic management and interacts fatally with azathioprine.
Recognizing contraindications and critical drug interactions is required to safely manage a medically complex patient.
3
Identify the mechanism of the most appropriate alternative therapy.
Anakinra or canakinumab are the targeted biologic agents of choice for acute gout when conventional therapies fail or are contraindicated. They function by neutralizing Interleukin-1 beta.
Gout pathogenesis involves crystal-induced activation of the NLRP3 inflammasome, which robustly produces Interleukin-1 beta.

Key Concept

The pathogenesis of acute gout involves monosodium urate crystal-induced activation of the NLRP3 inflammasome, leading to the production of Interleukin-1 beta. IL-1 beta inhibitors are indicated for acute flares when conventional therapies (NSAIDs, colchicine) are contraindicated due to severe renal or gastrointestinal comorbidities.
Question 277Question →

Match each clinical presentation of a paraneoplastic syndrome with its specific underlying pathophysiologic mechanism.

Click a left item, then click its matching right item

Items

A 64-year-old male with a central lung mass develops symmetric proximal muscle weakness that paradoxically improves following brief periods of repetitive exertion.
A 58-year-old female with a newly diagnosed solid renal mass presents with an asymptomatic elevation in hemoglobin (18.5 g/dL) and normal arterial oxygen tension.
A 71-year-old male with early satiety and weight loss rapidly develops dozens of intensely pruritic, stuck-on pigmented papules across his trunk.
A 66-year-old male with a neuroendocrine lung tumor presents with lethargy, a serum sodium of 118 mEq/L, and inappropriately concentrated urine.
A 52-year-old female with a cystic adnexal mass presents with acute psychiatric disturbances, memory deficits, and choreiform movements.

Matches

Show answer & explanation

Answer

Lambert-Eaton syndrome matches with presynaptic calcium channel antibodies; Paraneoplastic polycythemia matches with ectopic erythropoietin; Leser-Trélat sign matches with TGF-alpha production; SIADH matches with ectopic ADH; Anti-NMDA receptor encephalitis matches with NR1 subunit antibodies.
Each clinical scenario describes a specific paraneoplastic syndrome whose underlying molecular pathogenesis directly correlates with the accurately matched humoral or autoimmune process.

Step-by-Step Solution

1
Analyze the presentation of proximal weakness improving with use in the setting of a central lung mass.
Identify Lambert-Eaton myasthenic syndrome.
This syndrome is mediated by autoantibodies against presynaptic voltage-gated calcium channels, which differentiate it from myasthenia gravis.
2
Analyze the presentation of erythrocytosis with normal oxygenation and a renal mass.
Identify paraneoplastic polycythemia secondary to renal cell carcinoma.
This is driven by the ectopic, hypoxia-independent production of erythropoietin by the malignant cells.
3
Analyze the rapid appearance of seborrheic keratoses alongside gastrointestinal symptoms.
Identify the sign of Leser-Trélat.
The sudden cutaneous eruption is driven by tumor-secreted cytokines and growth factors, notably transforming growth factor-alpha (TGF-α).
4
Analyze the hyponatremia with concentrated urine in the setting of a neuroendocrine lung tumor.
Identify the Syndrome of Inappropriate Antidiuretic Hormone secretion (SIADH).
Small cell lung cancer can ectopically secrete ADH (a nonapeptide hormone), leading to unregulated free water retention at the collecting ducts.
5
Analyze the psychiatric changes and choreiform movements associated with a cystic adnexal mass.
Identify anti-NMDA receptor encephalitis.
This condition is classically associated with ovarian teratomas and is caused by autoantibodies cross-reacting with the NR1 subunit of NMDA receptors.

Key Concept

Paraneoplastic syndromes are systemic clinical disorders associated with malignancies that are mediated by tumor-secreted hormones, cytokines, or cross-reacting autoantibodies, rather than the physical mass of the primary tumor or its metastases.
Question 278Question →

A 28-year-old woman presents for follow-up after a recent hospital admission for an unprovoked deep vein thrombosis in her right lower extremity. She has no significant past medical history, does not smoke, and does not take oral contraceptives. Her mother had a pulmonary embolism at age 42. Laboratory evaluation demonstrates that the addition of activated protein C (APC) to the patient's plasma fails to appropriately prolong the activated partial thromboplastin time (aPTT). Which of the following is the most likely molecular mechanism underlying this patient's condition?

Show answer & explanation

Answer: Point mutation leading to an amino acid substitution in a coagulation factor

Answer

Point mutation leading to an amino acid substitution in a coagulation factor
The correct answer accurately describes the molecular mechanism of Factor V Leiden. Factor V Leiden is the most common inherited thrombophilia and is caused by a missense point mutation (G1691A) in the F5 gene. This mutation leads to a single amino acid substitution (arginine replaced by glutamine at position 506) in the Factor V protein. This specific alteration eliminates the cleavage site for activated protein C, rendering the mutated Factor Va resistant to degradation and resulting in a prolonged procoagulant effect.

Step-by-Step Solution

1
Identify the primary clinical diagnosis from the presentation and lab findings.
The patient has unprovoked venous thromboembolism, a strong family history, and laboratory evidence of activated protein C (APC) resistance, which is pathognomonic for Factor V Leiden.
Establishing the specific phenotype is required before determining the underlying genetic etiology.
2
Recall the specific molecular genetic defect associated with Factor V Leiden.
Factor V Leiden results from a point mutation (a single nucleotide substitution of adenine for guanine) in the F5 gene.
This single nucleotide change alters the amino acid sequence of the resulting protein.
3
Determine the functional consequence of the genetic defect.
The mutation causes an arginine-to-glutamine substitution at position 506. This is the exact site where APC normally cleaves and inactivates Factor Va. The substitution prevents cleavage, leading to prolonged coagulation.
Understanding how the structural change affects protein function confirms that an amino acid substitution in a coagulation factor is the correct mechanism.

Key Concept

Factor V Leiden is an inherited thrombophilia caused by a missense point mutation that leads to a single amino acid substitution in Factor V, rendering it resistant to degradation by activated protein C.
Question 279Question →

A 32-year-old man is diagnosed with human immunodeficiency virus (HIV) infection. His CD4 T-lymphocyte count is 450 cells/mm 3^3 and his HIV RNA viral load is 45,000 copies/mL. The physician plans to initiate an antiretroviral therapy regimen that includes abacavir. Before prescribing this medication, the physician orders a genetic test to prevent a potentially fatal, immune-mediated hypersensitivity reaction. The specific host allele being tested for encodes a protein that is normally involved in which of the following cellular processes?

Show answer & explanation

Answer: Antigen presentation to T cells

Answer

Antigen presentation to T cells
The patient is about to start abacavir, a nucleoside reverse transcriptase inhibitor (NRTI). Abacavir is strongly associated with a severe, potentially life-threatening hypersensitivity reaction in patients who carry the HLA-B*5701 allele. Therefore, pharmacogenomic screening for this allele is mandatory prior to drug initiation. The HLA-B gene encodes a major histocompatibility complex (MHC) class I molecule. In normal physiology, MHC class I molecules are present on the surface of all nucleated cells and are responsible for presenting endogenous antigens to CD8+ cytotoxic T cells. In susceptible individuals, abacavir binds non-covalently to the HLA-B*5701 protein, altering the presentation of self-peptides and triggering an inappropriate, systemic CD8+ T-cell response.

Step-by-Step Solution

1
Identify the mandatory genetic test required before initiating abacavir.
Clinical guidelines require testing for the HLA-B*5701 allele to prevent a severe, potentially fatal hypersensitivity reaction.
Abacavir is uniquely associated with an immune-mediated hypersensitivity reaction in patients carrying this specific allele.
2
Determine the normal physiological function of the protein encoded by this allele.
The HLA-B gene encodes a Major Histocompatibility Complex (MHC) class I molecule.
MHC class I molecules are expressed on all nucleated cells and are responsible for presenting endogenous antigens to CD8+ cytotoxic T cells.

Key Concept

Pharmacogenomic screening for the HLA-B*5701 allele is mandatory before starting abacavir; this allele encodes an MHC class I molecule involved in antigen presentation to T cells.
Question 280Question →

A 35-year-old woman presents to the clinic to discuss her risk for breast cancer. Her mother and maternal aunt were both diagnosed with breast cancer in their early 40s. The patient's mother recently underwent genetic testing and was told she has a pathogenic BRCA1 mutation. The patient is currently asymptomatic but is requesting genetic testing for herself to understand her risk. Arrange the following steps in the most appropriate standard sequence for the clinical genetic evaluation and management of this patient.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The most appropriate chronological order is: 1) Verify the specific familial mutation, 2) Conduct pre-test genetic counseling, 3) Obtain informed consent and collect the specimen, 4) Provide post-test counseling, and 5) Develop a personalized cancer screening and management plan.
In the context of predictive genetic testing for a known familial mutation (such as BRCA1), the established standard of care follows a specific sequence to ensure clinical accuracy and ethical practice. First, the exact pathogenic variant must be verified from the affected relative's official report to ensure the correct targeted molecular test is ordered. Second, comprehensive pre-test genetic counseling is mandatory to ensure the patient understands the psychosocial, medical, and financial implications. Third, after informed consent is obtained, a biological sample is drawn for the targeted molecular analysis. Fourth, post-test counseling is provided to interpret the results accurately for the patient. Finally, these molecular results are used to formulate a personalized, long-term clinical management and surveillance plan.

Step-by-Step Solution

1
Verify the familial mutation
The exact molecular target is identified
Ensures the correct targeted test is ordered instead of an unnecessary full sequencing panel.
2
Pre-test counseling
The patient is fully informed of the risks and benefits
Required for ethical genetic testing and informed decision-making prior to any procedure.
3
Consent and sample collection
The DNA sample is sent for targeted analysis
Initiates the actual molecular diagnostic process after the patient is fully informed.
4
Post-test counseling
The patient understands their genetic status
Critical for accurately interpreting complex molecular results for the patient.
5
Clinical management
A long-term surveillance plan is established
Applies the genetic findings to prevent or achieve early detection of future disease.

Key Concept

Clinical workflow for predictive genetic testing of familial mutations
PreviousPage 14 / 22Next
Foundational Science and Mechanisms of Disease Practice Questions — USMLE Step 3 — Page 14 | Examkin